SCV-07: Phase IIb started

SciClone began a double-blind, placebo-controlled Phase IIb trial to evaluate 0.1, 0.3 and 1 mg/kg doses of daily subcutaneous SCV-07 for 7 weeks in 160 patients with head and neck cancer receiving co...